Key Lessons from COVID-19: A Narrative Review Describing Qatar's Multifactorial Approach in Executing a Vaccination Campaign

• Published in: Vaccines (Basel) Vol. 11; no. 5; p. 953
• Main Authors: Albayat, Soha, Almaslamani, Muna, Alromaihi, Hamad, Khogali, Hayat, Mundodan, Jesha, Joury, Jean, Haridy, Hammam
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 06.05.2023; MDPI
• Subjects: Age groups; BNT162b2; Chronic illnesses; Coronaviruses; COVID-19 vaccines; Disease transmission; Epidemiology; Essential workers; FDA approval; Hospitals; Management; mass vaccination program; Migrant workers; Mitigation; Mortality; mRNA; mRNA-1273; Narratives; Pandemics; Population; Public health; Qatar; Quarantine; Review; Severe acute respiratory syndrome coronavirus 2; Vaccination; vaccination campaign; Vaccines; Qatar; United States > US; COVID-19 vaccines; vaccination campaign; BNT162b2; Qatar; mass vaccination program; mRNA-1273
• ISSN: 2076-393X; 2076-393X
• DOI: 10.3390/vaccines11050953

Widespread vaccination programs have been implemented in many countries to curtail the COVID-19 pandemic, with varying success and challenges. To better understand the successes and challenges of the global COVID-19 response in the face of emerging new variants and epidemiologic data, we discuss how Qatar engaged the healthcare sector, governmental bodies, and the populace to combat COVID-19, with a focus on the country's vaccination strategy. This narrative provides the history and timeline of the Qatar COVID-19 vaccination campaign; factors that helped the vaccination campaign and the transferable lessons learned are discussed. Details regarding how Qatar responded to challenges, such as vaccine hesitancy and mitigation of misinformation, are highlighted. Qatar was one of the first countries to procure the BNT162b2 (Comirnaty ; Pfizer-BioNTech, Pfizer Inc., New York, NY, USA) and mRNA-1273 (Spikevax ; Moderna, Cambridge, MA, USA) COVID-19 vaccines. A relatively high vaccination rate and low case mortality rate (0.14% as of 4 January 2023) was observed in Qatar compared with other countries (global case mortality rate, 1.02%). Learnings will be carried forward as a basis for addressing this evolving pandemic and any future national emergencies in Qatar.